Loading company…
Tenvie Therapeutics develops small-molecule therapies targeting inflammation and metabolic and lysosomal dysfunction.
Tenvie Therapeutics develops small molecules for diseases affecting the central nervous system and other parts of the body. Its pipeline targets inflammation, metabolic dysfunction and lysosomal dysfunction. The company was founded in 2025 and is based in South San Francisco, US. In January 2025, it raised USD 200 million in venture funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in